NCT02177175View on ClinicalTrials.gov

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 24, 2014

Primary Completion Date

June 24, 2021

Study Completion Date

June 24, 2021

Conditions

Breast Cancer

Interventions

DRUG

Carvedilol

OTHER

placebo

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering West Harrison, Harrison

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02177175 - Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification | Biotech Hunter | Biotech Hunter